MX2012004134A - Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico. - Google Patents

Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico.

Info

Publication number
MX2012004134A
MX2012004134A MX2012004134A MX2012004134A MX2012004134A MX 2012004134 A MX2012004134 A MX 2012004134A MX 2012004134 A MX2012004134 A MX 2012004134A MX 2012004134 A MX2012004134 A MX 2012004134A MX 2012004134 A MX2012004134 A MX 2012004134A
Authority
MX
Mexico
Prior art keywords
beta
combination therapy
receptor agonist
adrenergic receptor
antimuscarinic agent
Prior art date
Application number
MX2012004134A
Other languages
English (en)
Inventor
Hiroshi Nagabukuro
Scott D Edmondson
Mary Struthers Sinharoy
William S Denney
Tara L Frenkl
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2012004134A publication Critical patent/MX2012004134A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe en la presente un método mejorado para tratar vejiga hiperactiva, en donde el método comprende administrar a un paciente en necesidad del mismo un agonista del receptor adrenérgico beta 3, un agente antimuscarinico, y un antagonista M2 selectivo opcional; dicha terapia de combinación proporciona eficacia y/o efectos secundarios reducidos.
MX2012004134A 2009-10-07 2010-09-27 Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico. MX2012004134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24938609P 2009-10-07 2009-10-07
PCT/US2010/050328 WO2011043942A1 (en) 2009-10-07 2010-09-27 Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent

Publications (1)

Publication Number Publication Date
MX2012004134A true MX2012004134A (es) 2012-05-08

Family

ID=43857059

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004134A MX2012004134A (es) 2009-10-07 2010-09-27 Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico.

Country Status (15)

Country Link
US (1) US20120202819A1 (es)
EP (1) EP2485595A4 (es)
JP (1) JP5738871B2 (es)
KR (1) KR20120093859A (es)
CN (1) CN102638987A (es)
AU (1) AU2010303811B2 (es)
BR (1) BR112012007829A2 (es)
CA (1) CA2774992A1 (es)
IL (1) IL218756A0 (es)
IN (1) IN2012DN02782A (es)
MX (1) MX2012004134A (es)
NZ (1) NZ599233A (es)
RU (1) RU2012118668A (es)
WO (1) WO2011043942A1 (es)
ZA (1) ZA201202520B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
KR20130135239A (ko) * 2010-08-03 2013-12-10 앨씨알엑스, 인크. 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제
EP2706997B1 (en) * 2011-05-10 2019-03-27 TheraVida, Inc. Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
US9809536B2 (en) 2011-10-27 2017-11-07 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
TW201338772A (zh) * 2012-02-09 2013-10-01 Altherx Inc 藥學組合物
RS59402B1 (sr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
KR20210103589A (ko) * 2013-07-23 2021-08-23 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
WO2016081772A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP3324966A4 (en) * 2015-07-20 2019-04-10 Chase Pharmaceuticals Corporation MUSCARINIC COMBINATION OF A SELECTIVE M2 RECEPTOR ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR THE TREATMENT OF HYPOCHOLINERGIC DISORDERS
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination
CN111556753A (zh) * 2017-12-21 2020-08-18 杏林制药株式会社 用于夜间尿频的治疗剂
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789076B1 (fr) * 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2006042679A1 (de) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
EP2141992A1 (en) * 2007-03-29 2010-01-13 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3

Also Published As

Publication number Publication date
EP2485595A1 (en) 2012-08-15
CA2774992A1 (en) 2011-04-14
EP2485595A4 (en) 2014-03-12
CN102638987A (zh) 2012-08-15
BR112012007829A2 (pt) 2015-09-22
JP5738871B2 (ja) 2015-06-24
RU2012118668A (ru) 2013-11-20
IN2012DN02782A (es) 2015-09-18
KR20120093859A (ko) 2012-08-23
IL218756A0 (en) 2012-06-28
ZA201202520B (en) 2012-12-27
AU2010303811B2 (en) 2013-01-24
NZ599233A (en) 2013-04-26
US20120202819A1 (en) 2012-08-09
AU2010303811A1 (en) 2012-04-19
WO2011043942A1 (en) 2011-04-14
JP2013507363A (ja) 2013-03-04

Similar Documents

Publication Publication Date Title
MX2012004134A (es) Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico.
BR112012025017A2 (pt) métodos para melhorar a qualidade do sono.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
NZ600125A (en) Methods of treating or preventing acute erythema
PH12013501341A1 (en) Morphinan compounds
HK1145803A1 (en) Devices, formulations, and methods for delivery of multiple beneficial agents
MX2010005331A (es) Composiciones y metodos para tratamiento de purpura.
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
WO2009129432A3 (en) Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
WO2009129494A3 (en) Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
EP2019646A4 (en) METHOD, DEVICE AND SYSTEM FOR THE RELEASE OF A THERAPEUTIC ACTIVE IN THE EYE
NZ597031A (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)
MX353105B (es) Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva.
MX2013003638A (es) Tratamiento en combinacion para rosacea.
IN2012DN02423A (es)
WO2009052073A3 (en) Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
BRPI0916540B8 (pt) inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
EP2490700A4 (en) EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF
MX2020002741A (es) Uso de gaboxadol en el tratamiento de narcolepsia.
MX2011009482A (es) Metodo o sistema que usa biomarcadores para el monitoreo de un tratamiento.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2009003912A (es) Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas.
WO2009052075A3 (en) Method of treating motor disorders with alpha-2b adrenergic receptor agonists

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

HC Change of company name or juridical status

Owner name: MERCK SHARP & DOHME CORP.*

FA Abandonment or withdrawal